Clinical Trial

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2026 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
Trial Details
NCT Number NCT07480720
Lead Sponsor Elazıg Fethi Sekin Sehir Hastanesi
Conditions Graves Disease, Graves Ophthalmopathy
Enrollment 100 participants
Start Date 2026-03-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-18